04Nov/13

AIMM Therapeutics‚Äô Pre-fusion RSV Antibodies Facilitate Improved Approach … – PharmiWeb.com (press release)

AIMM Therapeutics’ Pre-fusion RSV Antibodies Facilitate Improved Approach
PharmiWeb.com (press release)
AIMM Therapeutics B.V. a leading developer of a new generation of therapeutic antibodies announced today that researchers have used the Company‚Äôs unique family of antibodies that neutralize respiratory syncytial virus (RSV) to engineer an improved 

04Nov/13

AIMM Therapeutics' Pre-fusion RSV Antibodies Facilitate Improved Approach to … – 4-traders (press release)

AIMM Therapeutics’ Pre-fusion RSV Antibodies Facilitate Improved Approach to
4-traders (press release)
AIMM Therapeutics B.V., a leading developer of a new generation of therapeutic antibodies, announced today that researchers have used the Company’s unique family of antibodies that neutralize respiratory syncytial virus (RSV) to engineer an improved 

and more »

04Nov/13

Researchers advise early stem cell transplant in Non-Hodgkin's lymphoma – Telemanagement


Telemanagement

Researchers advise early stem cell transplant in Non-Hodgkin’s lymphoma
Telemanagement
Researchers advise early stem cell transplant to reduce risk of relapse and higher longevity and better health. Non-Hodgkin’s lymphoma is traditionally treated by a 5-drug regimen R-CHOP. It puts the patients into remission. Those relapsing go for a 

04Nov/13

Simple tool to identify patients at risk of engaging in "medication tradeoffs … – News-Medical.net

Simple tool to identify patients at risk of engaging in “medication tradeoffs
News-Medical.net
Researchers conducted detailed, in-person interviews with 105 patients at the two transplant centers who underwent liver transplantation in 2011 and 2012 with the goal of exploring relationships between medication tradeoffs, medication non-adherence